Collegium Pharmaceutical, Inc. (COLL) held an investor conference call on March 19, 2026, to discuss its acquisition of AZSTARYS and relevant corporate subsidiaries from Corium Therapeutics. The deal aims to expand the company's position in the ADHD market. Executives including CEO Vikram Karnani joined the call.
On March 19, 2026, at 9:00 AM EDT, Collegium Pharmaceutical, Inc. (COLL) conducted an investor call focused on its acquisition of AZSTARYS from Corium Therapeutics. Ian Karp, Head of Investor Relations, opened the discussion, stating, 'welcome to Collegium Pharmaceutical investor call to discuss the acquisition of AZSTARYS and all relevant corporate subsidiaries from Corium Therapeutics, which significantly expands our position in ADHD.' The acquisition is intended to broaden Collegium's ADHD portfolio and accelerate growth, as noted in the call's title and description. Company participants included Vikram Karnani, CEO, President, Executive VP & Director; Scott Dreyer, Executive VP & Chief Commercial Officer; and Colleen Tupper, Executive VP & CFO, who were available for the Q&A session. Analysts from Jefferies LLC, Truist Securities, H.C. Wainwright & Co., Piper Sandler & Co., and Needham & Company joined as conference call participants. The call included standard disclaimers about forward-looking statements under the Private Securities Litigation Reform Act of 1995 and non-GAAP financial information, with risks detailed in SEC filings. No specific financial terms or completion timelines were detailed in the provided transcript excerpts.